Novel Wnt signaling and other pathway inhibitors in the colorectal cancer genomic landscape era

References

• 1  Van Cutsem E, Köhne CH, Láng I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol.29(15),2011–2019 (2011).
  Medline CASGoogle Scholar
• 2  Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol.27(5),663–671 (2009).
  Medline CASGoogle Scholar
• 3  Maughan TS, Adams RA, Smith CG et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised Phase 3 MRC COIN trial. Lancet377(9783),2103–2114 (2011).
  Medline CASGoogle Scholar
• 4  Tveit KM, Guren T, Glimelius B et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J. Clin. Oncol.30(15),1755–1762 (2012).
  Medline CASGoogle Scholar
• 5  Alberts SR, Sargent DJ, Nair S et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA307(13),1383–1393 (2012).
  Medline CASGoogle Scholar
• 6  Roukos DH. Next-generation sequencing and epigenome technologies: potential medical applications. Expert Rev. Med. Devices7(6),723–726 (2010).
  Medline CASGoogle Scholar
• 7  Chin L, Andersen JN, Futreal PA. Cancer genomics: from discovery science to personalized medicine. Nat. Med.17,297–303 (2011).
  Medline CASGoogle Scholar
• 8  Roukos DH. Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark. Med.4(4),583–586 (2010).
  Google Scholar
• 9  Misale S, Yaeger R, Hobor S et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature486(7404),532–536 (2012).
  Medline CASGoogle Scholar
• 10  Diaz LA Jr, Williams RT, Wu J, Kinde I et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature486(7404),537–540 (2012).
  Medline CASGoogle Scholar
• 11  Takada K, Zhu D, Bird GH et al. Targeted disruption of the BCL9/β-Catenin complex inhibits oncogenic Wnt signaling. Sci. Transl. Med.4(148),148ra117 (2012).
  MedlineGoogle Scholar
• 12  Seshagiri S, Stawiski EW, Durinck S et al. Recurrent R-spondin fusions in colon cancer. Nature488(7413),660–664 (2012).
  Medline CASGoogle Scholar
• 13  Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature487(7407),330–337 (2012).
  Medline CASGoogle Scholar
• 14  Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell144(5),646–674 (2011).
  Medline CASGoogle Scholar
• 15  Roukos DH. Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics11(8),1039–1043 (2010).
  CASGoogle Scholar
• 16  Roukos DH. Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics J.11(2),81–92 (2011).
  Medline CASGoogle Scholar
• 17  Califano A, Butte AJ, Friend S, Ideker T, Schadt E. Leveraging models of cell regulation and GWAS data in integrative network-based association studies. Nat. Genet.44(8),841–847 (2012).
  Medline CASGoogle Scholar
• 18  Ideker T, Krogan NJ. Differential network biology. Mol. Syst. Biol.8,565 (2012).
  MedlineGoogle Scholar
• 19  Camacho DF, Pienta KJ. Disrupting the networks of cancer. Clin. Cancer Res.18(10),2801–2808 (2012).
  Medline CASGoogle Scholar
• 20  Khatri P, Sirota M, Butte AJ. Ten years of pathway analysis: current approaches and outstanding challenges. PLoS Comput. Biol.8(2),e1002375 (2012).
  Medline CASGoogle Scholar
• 101  US FDA: Cetuximab in combination with Folfiri/Therascreen. www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm310933.htm
  Google Scholar
• 102  NCCN Guidelines. www.nccn.org/professionals/physician_gls/f_guidelines.asp#colon
  Google Scholar